Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.

Abstract

The correlation between imatinib (IM) trough plasma concentration (Cmin) and clinical response was assessed in patients with chronic-phase chronic myeloid leukemia. The Cmin correlated with neither the achievement of complete cytogenetic response (977 vs. 993 ng/ml, P = 0.48) nor a major molecular response (1,044 vs. 818 ng/ml, P = 0.17). Although this was… (More)
DOI: 10.1007/s12185-011-0838-3

Topics

5 Figures and Tables

Cite this paper

@article{Yoshida2011AdherenceTT, title={Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.}, author={Chikashi Yoshida and Takuya Komeno and Mitsuo Hori and Tomofumi Kimura and Masami Fujii and Yasushi Okoshi and K. Suzukawa and Shigeru Chiba and Yuichi Hasegawa and Harumi Yamamoto Mukai and Takayoshi Ito and Seiichi Shimizu and Masaharu Kamoshita and Daisuke Kudo and Atsushi Shinagawa and Norio Chikatsu and Yuriko Monma and Norimichi Watanabe and Hiroshi Kojima}, journal={International journal of hematology}, year={2011}, volume={93 5}, pages={618-623} }